Intech Investment Management LLC Boosts Stock Position in Omnicell, Inc. $OMCL

Key Points

• Intech Investment Management LLC increased its stake in Omnicell, Inc. by 75.6%, acquiring an additional 99,104 shares, bringing its total holdings to 230,171 shares valued at approximately $8.05 million.
• As of now, institutional investors own 97.70% of Omnicell's stock, highlighting a strong institutional interest in the company.
• Omnicell's latest earnings report revealed earnings per share (EPS) of $0.45, surpassing analysts' expectations, with revenues reaching $290.56 million for the quarter.

Intech Investment Management LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 75.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 230,171 shares of the company's stock after buying an additional 99,104 shares during the period. Intech Investment Management LLC owned about 0.49% of Omnicell worth $8,047,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Jane Street Group LLC grew its stake in shares of Omnicell by 201.5% in the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Omnicell by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after buying an additional 4,866 shares during the last quarter. Empowered Funds LLC increased its holdings in Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock valued at $348,000 after buying an additional 1,243 shares during the period. Coppell Advisory Solutions LLC grew its holdings in shares of Omnicell by 5,343.3% in the 1st quarter. Coppell Advisory Solutions LLC now owns 27,543 shares of the company's stock worth $1,053,000 after purchasing an additional 27,037 shares during the last quarter. Finally, NFJ Investment Group LLC lifted its position in Omnicell by 8.6% during the 1st quarter. NFJ Investment Group LLC now owns 38,993 shares of the company's stock valued at $1,363,000 after purchasing an additional 3,096 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. Bank of America raised their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler cut their price target on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company raised their price target on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $46.71.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 3,880 shares of Omnicell stock in a transaction on Friday, September 12th. The stock was sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares of the company's stock, valued at $3,679,212.25. The trade was a 3.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.52% of the company's stock.

Omnicell Price Performance

Shares of NASDAQ:OMCL traded up $0.02 on Wednesday, hitting $32.34. The company's stock had a trading volume of 88,755 shares, compared to its average volume of 558,813. The company has a market capitalization of $1.49 billion, a PE ratio of 64.79, a PEG ratio of 7.05 and a beta of 0.82. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The company has a 50-day simple moving average of $30.83 and a 200 day simple moving average of $30.97.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The firm had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. During the same period in the previous year, the firm earned $0.51 earnings per share. The business's revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.